{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:30:01Z","timestamp":1794396601690,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacadv.2026.102621","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:45:09Z","timestamp":1772232309000},"page":"102621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Second-Generation Aldosterone Synthase Inhibitors for Hypertension"],"prefix":"10.1016","volume":"5","author":[{"given":"Flavia","family":"Queiroga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-6114","authenticated-orcid":false,"given":"Leo","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Ujjawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensieh Sadat","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Costa Cruz Akabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8031-0601","authenticated-orcid":false,"given":"Nelson","family":"I. Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Valverde Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Krawisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Dibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102621_bib1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jacadv.2026.102621_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102621_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102621_bib4","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/eurheartj\/ehs368","article-title":"Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis","volume":"34","author":"Kumbhani","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102621_bib5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102621_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2026.102621_bib7","article-title":"Mineralocorticoid receptor antagonists and aldosterone synthase inhibitors: agent comparison with implications for clinical practice and trial design","author":"Ferreira","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2026.102621_bib8","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","article-title":"Adverse effects of mineralocorticoid receptor antagonist administration","volume":"24","author":"Kallistratos","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacadv.2026.102621_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102621_bib10","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"10.1016\/j.jacadv.2026.102621_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102621_bib12","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102621_bib13","series-title":"A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO)","year":"2023"},{"key":"10.1016\/j.jacadv.2026.102621_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/ATVBAHA.123.319220","article-title":"Use of genomics to develop novel therapeutics and personalize hypertension therapy","volume":"44","author":"Magavern","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2026.102621_bib15","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2026.102621_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102875","article-title":"Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta- analysis","volume":"49","author":"Siddiqui","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacadv.2026.102621_bib17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102621_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102621_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102621_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacadv.2026.102621_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2026.102621_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R package","volume":"93","author":"R\u00f6ver","year":"2020","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jacadv.2026.102621_bib23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jrsm.1475","article-title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis","volume":"12","author":"R\u00f6ver","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jacadv.2026.102621_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.121.057687","article-title":"Clinical trial design principles and outcomes definitions for device-based therapies for hypertension: a consensus document from the hypertension academic research consortium","volume":"145","author":"Kandzari","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102621_bib25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102621_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jrsm.1370","article-title":"Random-effects meta-analysis of few studies involving rare events","volume":"11","author":"G\u00fcnhan","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jacadv.2026.102621_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10618600.2016.1276840","article-title":"Discrete approximation of a mixture distribution via restricted divergence","volume":"26","author":"R\u00f6ver","year":"2017","journal-title":"J Comput Graph Stat"},{"key":"10.1016\/j.jacadv.2026.102621_bib28","series-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluation","author":"Spiegelhalter","year":"2003"},{"key":"10.1016\/j.jacadv.2026.102621_bib29","series-title":"Bayesian methods in pharmaceutical research","article-title":"Bayesian methods for meta-analysis","author":"Welton","year":"2020"},{"key":"10.1016\/j.jacadv.2026.102621_bib30","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"205","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jacadv.2026.102621_bib31","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0962280220982643","article-title":"A Bayesian dose\u2013response meta-analysis model: a simulations study and application","volume":"30","author":"Hamza","year":"2021","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jacadv.2026.102621_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102621_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030142","article-title":"Adverse effects of aldosterone: beyond blood pressure","volume":"13","author":"Brown","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2026.102621_bib34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102621_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacadv.2026.102621_bib36","series-title":"HALO TRIAL | Dr.Deepak Bhatt discusses Aldosterone Synthase Inhibitor in hypertension with Dr. Gaba","year":"2023"},{"key":"10.1016\/j.jacadv.2026.102621_bib37","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2026.102621_bib38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacadv.2026.102621_bib39","first-page":"30","article-title":"Bayesian analytical methods in cardiovascular clinical trials: why, when, and how","volume":"41","author":"Heuts","year":"2025","journal-title":"Can J Cardiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:50:31Z","timestamp":1793944231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772963X26000384"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102621","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-Generation Aldosterone Synthase Inhibitors for Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102621"}}